Sichenzia Ross Ference LLP Represents INmune Bio Inc. in an $8 Million Initial Public Offering and Listing on the Nasdaq Capital Market
Press Release – New York, NY – February 5, 2019 – Sichenzia Ross Ference (“SRF”), a leading securities and corporate law firm, is pleased to announce that the firm has represented INmune Bio Inc. (INMB), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system to fight disease, in an initial public offering at a price of $8.00 per share resulting in gross proceeds of approximately $8,000,000 and listing on the Nasdaq Capital Market under the ticker symbol INMB.
The SRF team was led by Partners Marc Ross, Thomas Rose and David Manno. View more of Sichenzia Ross Ference’s IPO transactions, here.
- Sichenzia Ross Ference Carmel LLP (思成律师事务所/SRFC) 代表 Ribbon Acquisition Corp 完成在纳斯达克交易所5000万美元的首次公开发行 (IPO) - January 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents Craft Capital Management in $600,000 Public Offering of Giftify, Inc. - January 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents Aegis Capital Corp. in $15 Million Public Offering of Li-Cycle - January 15, 2025